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Circulatory zinc transport is controlled by distinct interdomain 
sites on mammalian albumins  
Katarzyna B. Handinga,b, Ivan G. Shabalina,b, Omar Kassaarc, Siavash Khazaipoulc, Claudia A. 
Blindauerd, Alan J. Stewartc, Maksymilian Chruszcze, Wladek Minora, b   
Zinc is an essential nutrient in the body; it is required for the catalytic activity of many hundreds of human enzymes and 
virtually all biological processes, therefore its homeostasis and trafficking is of crucial interest. Serum albumin is the major 
carrier of Zn2+ in the blood and is required for its systemic distribution. Here we present the first crystal structures of 
human serum albumin (HSA) and equine serum albumin (ESA) in complex with Zn2+. The structures allow unambiguous 
identification of the major zinc binding site on these two albumins, as well as several further, weaker zinc binding sites. 
The major site in both HSA and ESA has tetrahedral geometry and comprises three protein ligands from the sidechains of 
His67, His247 and Asp249 and a water molecule. Isothermal titration calorimetric studies of a HSA H67A mutant confirm 
this to be the highest affinity Zn2+ site. Furthermore, analysis of Zn2+ binding to HSA and ESA proved the presence of 
secondary sites with 20-50-fold weaker affinities, which may become of importance under particular physiological 
conditions. Both calorimetry and crystallography suggest that ESA possesses an additional site compared to HSA, involving 
Glu153, His157 and His288. The His157 residue is replaced by Phe in HSA, incapable of metal coordination. Collectively, 
these findings are critical to our understanding of the role serum albumin plays in circulatory Zn2+ handling and cellular 
delivery.
Introduction 
Serum albumin (SA) is an abundant plasma transport protein (ca. 
600 μM), which is composed of three homologous domains. It is 
known to bind and transport a wide variety of molecules including 
fatty acids, hormones, drugs and metal ions.1,2 The ability to bind 
such a vast and diverse group of molecules is reflected in its flexible 
three-dimensional structure.3 Even in the absence of ligand, 
albumin is constantly sampling available conformational space in a 
process which has been described as “breathing”.1 Among many 
physiologically important molecules, albumin is the major carrier of 
Zn2+ in blood.4 Zn2+ is crucial for the activity of many hundreds of 
extra- and intracellular enzymes and transcription factors. 
Approximately 75-80 % of plasma Zn2+ (~14 μM) is bound to 
albumin, accounting for as much as 98% of the exchangeable 
fraction of Zn2+ in blood plasma.5 Serum albumin effectively acts as 
an extracellular “zinc buffer” that controls the concentrations of 
“free” Zn2+ ions that are available to other plasma proteins or for 
cellular uptake through membrane-bound zinc transporters.6 Thus, 
SA not only controls the uptake of Zn2+ into cells including 
endothelial cells7 and erythrocytes,8 but also protects blood cells 
and the endothelial cells which line the blood vessels from the 
otherwise toxic concentration of Zn2+ in plasma.9,10 Additionally, 
receptor-mediated transport of Zn2+ across the endothelium has 
been demonstrated with albumin-Zn2+ complexes in vitro.11  
 Serum albumin is also involved in the handling of Cu2+, 
Ca2+ and Mg2+ in mammals, helping to control the biologically active 
levels of these metals in the blood.12 Significantly, recent work has 
demonstrated that there is cross-talk between the binding of Zn2+ 
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and free fatty acids, turning albumin into a device that links plasma 
Zn2+ speciation with energy metabolism.13,14 Knowledge of the 
structural features that mediate this cross-talk is essential for 
understanding and influencing this metabolic link. 
 Based on equilibrium dialysis experiments and 113Cd NMR 
spectroscopic studies, two or three high-affinity Zn2+-binding sites 
have been suggested to exist on bovine (BSA) and human (HSA) 
serum albumins.15–18 One site is known to have considerably higher 
affinity towards Zn2+ than any other site(s); this site is known as site 
A or the multi-metal binding site.19 For HSA, the location of this site 
at a domain interface was suggested through site-directed 
mutagenesis and 111Cd NMR spectroscopy,20 and subsequent EXAFS 
and molecular modeling studies indicated the participation of His67 
and Asn99 from domain I, and His247 and Asp249 from domain II.9 
Besides Zn2+, this site can also bind other metal ions including Cu2+, 
Ni2+, Cd2+,19 and Co2+.21 A second putative Cd2+/Zn2+-binding site on 
various albumins is called site B;17 the existence of this site has been 
demonstrated by 111/113Cd NMR spectroscopy,15,17,20,22 but its 
location has remained unknown. A third, weak site for both Cd2+ 
and Zn2+ has been suggested by equilibrium dialysis,22 but this has 
not been observed by any other technique. In addition, up to a 
further nine still weaker sites were detected by gel filtration 
chromatography.23 At present there is no evidence relating to the 
locations of any Zn2+ sites on albumin other than site A. These 
secondary Zn2+ sites on serum albumin extend the zinc binding 
capacity of albumin and may be biologically important, especially 
when site A is impacted by fatty acid binding13,14 and/or the Zn2+ 
concentration is very high. 
 Despite the critical role of albumin in the circulatory 
handling of Zn2+, there are no structural data related to specific 
binding sites on serum albumin and their geometry in the Protein 
Databank (PDB). Furthermore, only in 2012 were structures of 
serum albumins from mammalian species other than humans 
deposited in the PDB.24,25 Here, we present the first crystal 
structures of human serum albumin (HSA) and horse serum albumin 
(ESA) in complex with Zn2+ at different concentrations. We discuss 
the location, geometry, and residues involved in metal coordination 
in several Zn2+-binding sites. The crystallographic studies, together 
with results from isothermal titration calorimetry (ITC), provide 
conclusive evidence for the location of the major zinc site in both 
human and horse albumins. Furthermore, both structural and ITC 
analysis revealed differences in Zn2+ binding at secondary sites 
between the two albumins, suggesting that circulatory Zn2+ 
handling may differ between the two species.  
Results 
Overall albumin structure 
One HSA and five ESA crystal structures in complex with Zn2+, 
obtained by co-crystallization and soaking, are presented here 
(Table 1, Table 2). In general terms, HSA and ESA structures are 
highly similar, as may be expected given the 76.2% sequence 
identity and 84.8% sequence similarity between HSA and ESA. All six 
structures resemble the canonical “heart shape” composed of 
helices and loops (Fig. 1). Each structure can be divided into three 
homologous domains (from now on residue numbering will refer to 
HSA): I (residues 1–195), II (196–383) and III (384–585), each 
containing two sub-domains (A and B) composed of four and six 
alpha-helices, respectively (Fig. 1). Structures are additionally 
stabilized by 17 conserved disulfide bridges. The refined 
crystallographic models display good overall geometry with a low 
percentage of rotamer outliers and a low MolProbity clash score 
(Table 2). 
 
Zinc detection and identification in the structures 
The position and identity of the metal in each distinct metal binding 
site were confirmed by the characteristic anomalous scattering of 
zinc for both HSA and ESA structures with various approaches. First, 
for five of the structures (Table 2) the diffraction data were 
collected on the selenium absorption K-edge (12664 eV), which is 
above the zinc absorption K-edge (9659 eV), ensuring significant 
signal from Zn2+ on anomalous electron density maps. The presence 
of anomalous peaks indicated the positions of Zn2+ in the unit cell 
and enabled correct placement of Zn2+ ions even in low resolution 
structures. Second, to confirm that the anomalous signal was 
produced by zinc, the X-ray fluorescence spectra at excitation 
wavelengths above (9668 eV) and below (9618 eV) the zinc 
absorption K-edge were recorded for the crystal with the highest 
Zn2+ concentration at neutral pH (Table 2, 5IJE). In the spectra at the 
excitation energy of 9668 eV there were two peaks, at 9600 and 
8660 eV (Fig. S1). The first peak corresponds to the energy of the 
incident X-ray beam. The peak at 8660 eV refers to the K-level 
emission line for zinc. Disappearance of the K-level zinc emission 
peak in the fluorescence spectrum collected at the excitation 
energy of 9618 eV proves that the anomalous scatterer is zinc. 
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Third, for the same crystal (Table 2, 5IJE), two diffraction data sets 
were collected at energies above (9668 eV) and below (9618 eV) 
the zinc absorption K-edge. The subsequent calculation of the 
anomalous map showed that the strong anomalous peaks 
interpreted as Zn2+ in the first experiment (data collected above zinc 
absorption K-edge) disappeared in the second experiment, proving 
that the anomalous peaks were caused by the bound Zn2+. Given 
the similarity of experimental setup (same protein source and 
buffer solutions), we present here X-ray fluorescence scan results 
and diffraction data collected below the zinc absorption K-edge only 
for one crystal. However, at least 10 similar experiments for crystals 
originating from different crystallization plates and drops were 
performed to ensure the identity of the metal in the structures. 
Furthermore, no significant anomalous signal was detected in 
diffraction data collected at energies above the zinc absorption K-
edge for ESA crystals produced without addition of ZnCl2, 
suggesting that all the significant anomalous signal observed in our 
structures is a result of addition of ZnCl2.  
 
Structure of HSA in complex with zinc 
The crystal structure of defatted HSA in complex with Zn2+ was 
obtained by co-crystallization in the presence of 0.5 mM ZnCl2, and 
is the first crystal structure of HSA determined at basic pH (pH 9, 
Table 1). The crystal belonged to space group C2221 with one 
protein molecule in the asymmetric unit (Table 2). The same space 
group has been reported before only for the structure of HSA in 
complex with the albumin-binding module from Finegoldia magna, 
but with significantly different cell dimensions (1TF0).26 The 
structure was refined at 2.65 Å resolution. The HSA-Zn2+ complex 
adopts a conformation closely similar to the structure of native HSA 
(1AO6)27 crystallized in the P1 space group (C-alpha RMSD 0.7 Å, 
571 atoms) as well as to the previously mentioned structure 1TF0 
(C-alpha RMSD 1.0 Å, 556 atoms). The structure has a high mean 
atomic displacement parameter (B-factor) for the protein atoms - 
90 Å². The high B-factor can be explained by the well-known high 
structural flexibility of HSA, which results in a number of surface 
residues having uninterpretable or absent electron density for their 
sidechains. As previously observed, the N-terminal part of the 
protein is disordered28 and the two first amino acids, Asp1 and Ala2, 
cannot be unambiguously built.  
The structure of HSA in complex with Zn2+ was crystallized 
at approximately 1:1 protein:zinc ratio (0.7 mM HSA and 0.5 mM 
ZnCl2, Table 1), and only one strong Zn
2+-binding site was 
confidently detected (Table 3, site I). There was one additional 
anomalous peak between His9 and Asp13, at the interface of a 
crystal contact, but Zn2+ could not be confidently built in this 
position due to its location on the unit cell edge. 
 
Structures of ESA in complex with zinc 
Five different complexes of defatted ESA with Zn2+ were 
determined in order to investigate the influence of pH and Zn2+ 
concentration on Zn2+-binding sites. The resolution of the structures 
spanned the range of 2.20 – 2.55 Å (Table 2). All structures of ESA-
Zn2+ complexes were obtained by initial co-crystallization in the 
presence of 2.5 mM Zn2+ for the structures at near-neutral pH, and 
50 mM Zn2+ for the structure at pH 4.5 (Table 1). Co-crystallization 
at neutral pH and higher zinc concentration did not produce 
diffraction quality crystals. In order to obtain crystals with higher 
zinc concentration, crystals obtain by initial co-crystallization in the 
presence of 2.5 mM Zn2+ were additionally soaked with ZnCl2 at 
final Zn2+ concentrations of 10, 15, and 30 mM resulting in 
structures 5IIU, 5IIX and 5IJE, respectively. 
All five structures have the same space group P61 and 
very similar unit cell parameters (Table 2) as the ESA apo form 
(3V08).25 The structures have one ESA molecule in the asymmetric 
unit and show similar protein conformation among each other as 
measured by low pairwise C-alpha RMSD values in the range of 0.31 
– 0.66 Å. The C-alpha atoms superpositions of Zn2+-bound ESA with 
its apo form (3V08)25 shows RMSD values in the range of 1.10 – 1.16 
Å, however when comparing to the structure at basic pH 9.0 
(5HOZ), the RMSD value is much lower and varies between 0.31 and 
0.67 Å. The average B-factor for protein atoms in Zn2+-bound 
structures varies in the range of 58-64 Å². It was not possible to 
unambiguously build either two or three N-terminal residues in any 
of the structures because of the dynamic character of this protein 
region. Thus, the N-terminus of ESA seems to behave in a similar 
way to that of HSA. 
In the structures of ESA in complex with Zn2+, the number 
of Zn2+ ions varied from one to 15 (Table 3). The varying number of 
occupied Zn2+-binding sites in the structures is related to changes in 
Zn2+ concentration (10 to 200-fold excess of Zn2+) and pH in 
crystallization conditions (Table 1). Zn2+ was placed only in sites that 
had a corresponding anomalous signal at least at the 4.0-5.3 σ level 
(depending on the structure). For most sites, we were able to 
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determine complete Zn2+coordination spheres composed of atoms 
originating from protein sidechains and water molecules. In these 
cases, tetrahedral coordination of metal was observed. For 9 sites, 
high anomalous peaks ensured Zn2+ placement, but the electron 
density map did not allow for confident building of full coordination 
spheres in at least one of the structures. There were additional 
peaks in all ESA structures on the verge of detection and with no 
detectable inner-sphere coordination, where Zn2+ ions could not be 
confidently placed.  
 
Zinc binding site A: geometry and dynamics 
All six structures contained a Zn2+ ion bound in the location 
corresponding to site A (Table 3, site I and I’). In three structures, 
namely those with the lowest Zn2+ concentrations (5IJF, 5IIH,  
obtained by co-crystallization, and 5IIU, obtained after additional 
soaking, Table 1), the Zn2+ ion is bound in site A by His67, Asp249, 
and His247 (Fig. 2, Fig. 3A), however in three other structures (5IIX, 
5IJE, obtained by additional soaking, and 5IJ5, obtained by co-
crystallization at low pH and the highest Zn2+ concentration), His247 
is not involved in Zn2+ coordination due to a conformational change 
of its sidechain (Fig. 3B, Fig. 3C). 
In the HSA structure, crystallized with 0.7 mM HSA and 
0.5 mM Zn2+, site I is the only site that could be confidently 
modeled. The same is true for the ESA structure 5IIH crystallized 
with 0.2 mM ESA at pH 7.4 in presence of 2.5 mM Zn2+. It may be 
concluded that under near-stoichiometric and even slightly higher 
ratios of Zn2+ vs. serum albumin, only the strongest site(s) will 
become occupied, and that site I corresponds to the primary zinc 
binding site on HSA and ESA, i.e. site A. The site A found in the X-ray 
structures reported here adopts a tetrahedral geometry, involving 
three protein atoms: NE2 from His67, ND1 from His247, and OD2 
from Asp249 plus a water molecule.  
The all-atoms superposition of residues within 8 Å from 
Zn2+ in site A (16 residues, 110 atoms) in the HSA-Zn2+ complex 
(5IJF), and the corresponding residues in a ligand-free HSA structure 
(1AO6) shows only slight differences for the positions of the 
residues, as reflected in a low all-atom RMSD value of 0.4 Å (Fig. 
2A). Similar calculation for native ESA (3V08) and ESA-Zn2+ complex 
(5IIH) shows a higher RMSD value of 1.2 Å (17 residues, 140 atoms). 
The higher RMSD value for ESA structures is caused by slightly 
different conformations of His67 and His247 sidechains 
participating in Zn2+ coordination and a nearby sidechain of Glu252, 
but the positions of C-alpha atoms remain the same. This finding 
indicates that site A in both HSA and ESA is mostly pre-organized in 
the fatty acid free form, however the adjustment of sidechain 
conformations may be necessary in order to coordinate Zn2+. The 
all-atom superimposition of residues within 8 Å from Zn2+ in site A 
in HSA-Zn2+ (5IJF) and ESA-Zn2+ (5IIH) also shows no significant 
structural differences (Fig. 2B) which suggests conservation of this 
site between the two organisms and probably other species, 
especially where residues coordinating Zn2+ are conserved (Fig. S2). 
The structures of serum albumin in complex with Zn2+ 
obtained at different ZnCl2 concentrations and pH illustrate the 
interesting dynamic behavior of the His247 sidechain (Fig. 3, Table 
3). In the structures of serum albumins with lower Zn2+ 
concentration (0.5 – 10.0 mM) and neutral or basic pH (PDB IDs: 
5IJF, 5IIH, 5IIU), the His247 sidechain is involved in Zn2+ 
coordination in site A (Fig. 3A). In the structures of ESA with very 
high Zn2+ (30-50 mM) and/or proton concentration (PDB IDs: 5IJE, 
5IJ5), the His247 sidechain adopts a different rotamer and is flipped 
away from the Zn2+ ion in site A and coordinates an additional Zn2+ 
ion (site XIV, Fig. 3B). In the structure of ESA obtained with 15 mM 
Zn2+ at pH 6.5, an intermediate state can be observed (5IIX): the 
sidechain of His247 is also flipped away from the Zn2+ in site A, 
however it is coordinating a water molecule instead of a Zn2+ ion 
(Fig. 3C). It is thus likely that the alternative His247 conformation in 
ESA-Zn2+ complexes is favored at lower pH and/or high Zn2+ 
concentration. 
 
Secondary and tertiary zinc binding sites 
The structures of ESA-Zn2+ complexes that were soaked at final Zn2+ 
concentrations of 10 mM or higher revealed that besides the main 
“primary” Zn2+-binding site I (site A), many additional sites can be 
populated with Zn2+ (Table 3). All sites with complete coordination 
spheres adopted tetrahedral geometries (Fig. 4). Sites where Zn2+ is 
coordinated by three protein residues and likely bind Zn2+ strongly 
enough to contribute to its handling/carriage in vivo will be referred 
to as secondary sites. Sites coordinated by one or two sidechains 
and expected to bind Zn2+ more weakly are referred to as tertiary 
sites.  
There are two secondary sites (II and III, Table 3) in ESA 
structures where Zn2+ is coordinated by three residues, like in site I. 
Site II is located at the highly disordered N-terminal part of SA and 
was found only in one ESA structure (5IIU). In site II, Zn2+ is bound 
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by one histidine residue and two carboxylates (His9, Asp13, and 
Asp255). Interestingly, in structures with higher zinc concentration, 
the anomalous signal for Zn2+ in this position was not present, and 
therefore Zn2+ was not placed in these structures. In the structure 
of HSA in complex with Zn2+, there is a weak anomalous signal 
present next to His9 and Asp13. However, the close proximity of a 
symmetric copy of the molecule in the HSA crystal (distance 
between His9 backbone and its asymmetric copy equals 4.0 Å) and 
location of the peak on the unit cell edge made it difficult to 
confidently model this Zn2+-binding site. Site III is located between 
domains IB and IIA and is present in all structures with 10 mM or 
higher Zn2+ concentration. Similarly to site A, site III is formed by 
two histidine residues (His157 and His288) and one carboxylate 
(Glu153). These residues are only partially conserved in mammalian 
albumins; His157 is replaced by Phe in HSA, suggesting weaker 
binding of Zn2+ in HSA in this location.  
Of the six tertiary Zn2+ sites consisting of two residues (IV-
IX), four are formed by a single histidine and a single carboxylate 
(Glu or Asp), one is formed by an aspartate residue and a main-
chain oxygen (site V), and one is located on a crystallographic 
contact (site VI). Four of the tertiary sites consisting of two residues 
are conserved in HSA, but site VII is unlikely to be involved in Zn2+ 
binding in HSA due to substitution of His318 and Asp312 by Ser and 
Asn, which have no strong Zn2+-binding ability. In the crystals 
prepared with 10 mM or higher Zn2+ concentration, zinc was also 
located in several sites that have only one amino acid ligand (Table 
3); these sites are not deemed to be of significance under 
physiological conditions. Interestingly, two of these sites (sites XII 
and XIII) have recently been implicated in Ru3+ binding.29 In none of 
the crystal structures was the N-terminal amine ordered, and no 
involvement in Zn2+ coordination was apparent; instead, His3 
formed part of the two-residue site IV.  
 
Measurement of zinc binding to albumins by Isothermal Titration 
Calorimetry (ITC) 
We used ITC to examine the Zn2+-binding properties of HSA, a 
mutant form of HSA (H67A), and ESA at near-physiological pH and 
ionic strength (50 mM Tris, 140 mM NaCl, pH 7.4). The resultant 
isotherms are shown in Fig. 5. Zn2+-binding to each protein under 
these conditions was exothermic. It should be noted that Tris 
possesses weak Zn2+-binding ability (log K = 2.27)30,31 which 
prevents formation and precipitation of Zn(OH)2 and thus ensures 
that Zn2+ remains in solution during the titrations. The competition 
from 50 mM Tris (which represents a 1000-fold excess over protein) 
also effectively prevents the detection of weak, non-physiological 
Zn2+ sites on the proteins. Thus only Zn2+-binding at reasonably 
strong sites (KD < 10
-3 M) can be observed under these conditions. 
Various models were explored to fit the resultant data 
corresponding to the binding of Zn2+ to HSA; a “two sequential 
sites” model fitted the data for HSA and H67A mutant well, with no 
substantial improvement of goodness-of-fit upon inclusion of a 
third binding site (Fig. 5A). This strongly indicates that under the 
experimental conditions, there are indeed only two sites with 
significant affinity in wild-type HSA, displaying a log K1ITC value of 
5.36 ± 0.05 and a log K2ITC value of 3.8 ± 0.1, where K1 likely 
corresponds to site A, and K2 to one secondary site. Taking into 
account the competition with 50 mM Tris, these values can be 
converted into conditional dissociation constants, valid at the pH 
and ionic strength applied, giving KD1 = 1.7 ± 0.3 µM, and KD2 = 65 ± 
21 µM. The values are in broad agreement with previous 
studies.13,14 Data fitting for the H67A mutant resulted in values for 
log K1ITC = 4.64 ± 0.10 and log K2ITC = 3.9 ± 0.1, giving KD1 = 9.1 ± 2.9 
µM and KD2 = 51 ± 16 µM.   The significantly decreased affinity to 
the first site indicates that the H67A mutation weakened binding to 
HSA by a factor of about 5. A similar conclusion had been reached 
previously by equilibrium dialysis.9 In contrast, the Zn2+-binding data 
for ESA were best fitted using a "three sequential sites" model (Fig. 
5B), yielding log K1ITC = 5.75 ± 0.10 (likely site A; KD1 = 0.7 ± 0.2 µM), 
log K2ITC  = 4.5 ± 0.1 (KD2 = 13 ± 4  µM) and log K3ITC  = 4.0 ± 0.1 (KD3 
= 41  ± 13  µM). This suggests that ESA harbors an additional Zn2+-
binding site compared to HSA, with its affinity lying between that of 
site A and the second HSA site. 
 
Discussion 
The importance of albumin in Zn2+ handling and transport has been 
widely studied;18 however, the locations and structures of individual 
Zn2+-binding sites on the albumin molecule have so far only been 
inferred indirectly. Here we present the first crystal structures of 
two serum albumins in complex with Zn2+. Our crystallographic 
studies provide new insights into the geometry of the main high-
affinity Zn2+-binding site on albumin (site A) and identify several 
secondary and tertiary Zn2+-binding sites. Additionally, examination 
of structures corresponding to albumins at different pH values and 
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in the presence of various Zn2+ concentrations provides insight into 
the structural dynamics of a crucial inter-domain histidine residue, 
His247, located at the domain I/II interface.  
 
Site A: location, structure, and dynamics 
Site A has long been thought to be the strongest Zn2+-binding site 
on albumin,15 and its location has previously been pinpointed 
through site-directed mutagenesis.20 Our studies further support 
this notion by the observation that the corresponding site is 
occupied by Zn2+ in all presented structures, even when crystallized 
in the presence of sub-stoichiometric zinc concentrations (e.g. in 
HSA). The crystallographic data reveal that the geometry and 
residues involved in Zn2+ coordination at site A are conserved 
between HSA and ESA. Inspection of albumin protein sequences 
from 14 different mammalian species suggests high conservation of 
this site across mammals (Fig. S2).  
The structures obtained at neutral or basic pH and lower 
zinc concentrations (5IJF and 5IIH obtained by co-crystallization, 
and 5IIU obtained by additional soaking, Table 1) likely best reflect 
the situation in physiological conditions. Comparison of these 
structures with their metal-free equivalents testifies to the high 
degree of pre-organization of site A (Fig. 2). The tetrahedral Zn2+ 
coordination sphere of site A observed in these crystal structures 
(inner-sphere ligands: sidechains of His67, His247, Asp249, and a 
water molecule) shares three protein residues with previously 
proposed models.9,20 The previous models and the structures 
presented here differ in the presence/absence of coordinative 
bonds to the sidechain OD1 of Asn99 and the backbone carbonyl 
oxygen of His247 that were included in the model based on 
interpretation of EXAFS data for wild-type and mutant HSA and 
optimization by force-field-based energy minimization. These 
differences are brought about mainly by the different position of 
the Zn2+ ion; a direct comparison between the serum albumin-Zn2+ 
crystal structures and the model reveals that the predicted location 
of the Zn2+ ion differs by 2.05 – 2.11 Å from that found by structure 
determination (Fig. S3). In consequence, the amide OD1 atom of 
Asn99 is at a distance of 3.9-4.4 Å and the backbone O of His247 at 
3.6–4.8 Å from the Zn2+ in all studied crystal structures. Both 
distances are too long for coordinative bonds, although charge-
dipole interactions cannot be ruled out. We considered the 
possibility for outer-sphere coordination, i.e. via a Zn2+-bound water 
molecule, but the electron density maps did not support this 
possibility. 
The ability of carbonyl oxygens from an amide or ester 
group to coordinate Zn2+ is well-documented,32 especially during 
ester and amide hydrolysis. Such bonds are both relatively weak 
and labile, and indeed, replacement of Asn99 by His or Asp has 
been shown to strengthen zinc binding to albumin about 10-fold.9 
Whilst this does not allow inferring Asn99 coordination in the wild-
type, we speculate that zinc binding to site A may be more dynamic 
than reflected by either structure or model, a suggestion that is in 
keeping with the outstandingly high flexibility of albumin in general. 
The tetrahedral site observed here resembles a classical catalytic 
site found in many hydrolytic enzymes.33 Despite earlier suggestions 
that metal transport sites should substantially differ from catalytic 
sites34 due to their fundamentally different mechanistic roles, many 
recent structural studies on zinc transport proteins have, 
surprisingly, revealed transport sites that similarly resembled 
catalytic sites.35 
The structures obtained at high zinc and/or proton 
concentrations (5IIX and 5IJE obtained by additional soaking, and 
5IJ5 obtained by co-crystallization, Table 1) have revealed a further 
dynamic aspect of site A that is located at the domain I/II interface: 
His247 can exist in at least two different conformations (Fig. 3). In 
the structures with low zinc and/or proton concentration, His247 
participates in zinc coordination in site A. With increasing zinc 
and/or proton concentration, His247 flips away from site A and 
either interacts with a water molecule, or coordinates an additional 
zinc ion. Protonation of His247, or over-saturation with Zn2+, seems 
to favor a conformation in which the sidechain is flipped away from 
Zn2+ in site A. We do not anticipate that the “flipped-away” 
conformation plays any significant role in physiological zinc-bound 
states of albumin, but speculate that it has significance in the 
context of the so-called neutral-to-basic (N-to-B) transition. In the 
majority of published albumin structures, the sidechain of His247 
forms a H-bond to that of Asp249, which in turn has a H-bond with 
His67. The interaction between these three residues (which 
incidentally also form the zinc binding site A) thus stabilizes the 
domain I/II interface, which otherwise has a scarcity of other 
stabilizing electrostatic or non-covalent interactions. The dynamic 
behavior of His247, pointed out on the basis of ESA-Zn2+ structures, 
is also observed in previously published native structures of serum 
albumin, but without direct correlation with pH. For example in 
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ESA, His247 is H-bonded to Asp249 in one reported X-ray crystal 
structure (4F5T, pH 4.5)24 (the pH values for these structures were 
taken as reported in PDB entries and do not necessarily reflect final 
pH in the crystallization drops),36 but is flipped away in three other 
structures (PDB IDs: 3V08, pH 7.4; 4F5S, pH 6.5; 5HOZ, pH 9.0).24,25 
Likewise for HSA, the His247-Asp249 H-bond is present in the 
structure 1AO6 at pH 7.5,27 but the sidechain of His247 points away 
from Asp249 in 4K2C at pH 7.0.37 It has been known for a long time 
that albumin undergoes various pH-dependent conformational 
transitions, and that the N-to-B transition is mediated by the 
protonation state of domain-interface histidine residues, as the only 
residues with pKa values in the neutral range.
38,39 This 
“conformational transition” should not be envisaged as a large 
change in the mutual orientation of entire domains, but rather as a 
subtle change in conformational dynamics at the domain I/II 
interface. As one of the very few H-bonding residues at this 
interface, His247 is likely a key player in these dynamics. The 
binding of several ligands to albumin, including drugs and fatty 
acids, have been shown to depend on the state of the N-B 
equilibrium, due to differences in affinity of the N and B states.40 
This is likely to be of importance physiologically, not least in 
pathological conditions associated with alkalosis, including 
hypoalbuminemia.41 
 
Secondary zinc binding sites: determining the location of site B 
We have previously demonstrated that site A undergoes significant 
disruption upon binding of fatty acids to albumins (HSA and BSA) 
such that the Zn2+ binding affinity of this site is significantly affected 
in the presence of physiological (and pathophysiological) 
concentrations of fatty acids.6,14 In addition, we have shown that 
there is an overlap in residues involved in Ca2+ binding.25 These 
observations raise the question how Zn2+ binding changes when site 
A is compromised and underlines the biological importance of 
additional Zn2+-binding site(s) on serum albumin. The structures 
corresponding to crystals grown in the presence of higher Zn2+ 
concentrations give insight into the possible locations of these Zn2+ 
sites. Zn2+ was found associated with ESA in 17 different locations, 
in addition to site A, which is in agreement with results of gel 
filtration chromatography.23 In 15 of the 17 sites, Zn2+ is 
coordinated by only one or two protein residues (called herein 
tertiary sites) and due to their expected lower binding affinity, 
these are not likely to have an impact on Zn2+ transport in vivo.  
In addition to the main site A and 15 tertiary sites, two 
secondary Zn2+-binding sites were located in ESA-Zn2+ structures 
(Table 3). Our own ITC measurements, as well as various literature 
reports9,16,21,23 suggest that in solution, there are only either one or 
two zinc binding sites with significant affinity besides site A in HSA 
or BSA. We suggest that these additional sites correspond to 
secondary sites in ESA-Zn2+ crystal structures. The secondary sites 
provide additional Zn2+-binding capacity on serum albumin and 
likely contribute to Zn2+ handling/transport in the circulation, 
particularly when site A is disrupted. Historically, this capacity has 
been ascribed to the so-called site B which is suggested to be the 
second strongest Zn2+-binding site on HSA and BSA.4 There has been 
much uncertainty about the location of site B. Out of two secondary 
sites (sites II and III), only one of them, site II (composed of 
His9/Asp13/Asp255) is conserved in HSA and BSA. The coordination 
sphere of Zn2+ then consists of one nitrogen atom from His and two 
oxygen atoms from Asp, in broad agreement with 113Cd2+ NMR data 
that predicted one or no nitrogen ligand with otherwise all-oxygen 
coordination for site B.17 Considering the observation of weak 
anomalous electron density near His9/Asp13 in the HSA structure at 
low zinc concentration, together with the presence of this site in 
the 5IIU ESA structure, this site appears as a particularly attractive 
candidate for site B. Intriguingly, this site would also be an inter-
domain site, and indeed, previous ITC measurements and 111Cd 
NMR spectroscopic studies13 on BSA indicated that the secondary 
zinc site, and Cd site B, were also affected by myristate binding. 
Two of the corresponding site II residues in BSA (Asp13 and Asp254) 
have also previously been implicated in Ca2+ binding.24 This suggests 
that cross-talk may exist between Zn2+ and Ca2+ binding at this site, 
similarly to site A.  
Site III in ESA is also formed by three protein ligands 
(composed of His157/His288/Glu153), similar to site A and site II, 
but this site is not conserved in HSA. Our ITC measurements 
indicated that ESA contains one binding site more than HSA; we 
suggest that this extra site corresponds to site III, and, based on the 
magnitude of the KD values, that it is associated with KD2. Site III has 
similar coordination and geometry (two His, one Asp residue, and 
one water molecule in tetrahedral geometry) as site I, but much 
weaker affinity for zinc (0.7 µM in site I vs. 13 µM in site III). The 
observed differences may be attributed to differences in the local 
environment. In site I, there is a negatively charged Glu252 residue 
within 6 Å from the Zn2+ -binding site that will electrostatically 
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stabilize the positively charged metal ion in site I. In addition, the 
previously mentioned carbonyl oxygens from the backbone of 
His247 and the amide sidechain of Asn99 may also contribute to 
stability through electrostatic interactions. Conversely, site III is in 
the vicinity of two positively charged residues, Arg188 (Glu in HSA) 
and Arg257. Arg188 is within 6 Å from the Zn2+-binding site, which 
may cause electrostatic repulsion. Arg257 is also within 3.5 Å from 
Glu153 that coordinates Zn2+ in site III. The interaction between 
Arg257 and Glu153 is likely to reduce the affinity of Glu153 for Zn2+. 
Interestingly, one of the residues forming site III (His288) has also 
been implicated in binding of Pt2+ to HSA.42 
 
ATCUN motif and free Cys34: no structural evidence for zinc 
binding 
Several metal-binding sites on albumins have been described in the 
literature; in particular, the N-terminal ATCUN (amino-terminal 
copper- and nickel-binding) motif43 and the free thiol at Cys34,4 but 
neither was seen to play a role in Zn2+ binding in our crystal 
structures. The N-terminus in albumins is very flexible which 
impedes the interpretation of crystallographic data (the first two or 
three residues cannot be built). The first three residues of most 
albumin sequences, e.g. Asp1-Ala2-His3 in HSA, form the 
aforementioned ATCUN motif, observed in several different 
proteins. The ATCUN motif is particularly suitable for coordination 
of metal ions with a preference for tetragonal or square planar 
geometry like Cu2+ and Ni2+, with concomitant deprotonation of two 
backbone amide nitrogens.44 In principle, and as shown by studies 
involving tripeptides, other metal ions, including Zn2+ and Co2+, can 
also bind to an ATCUN motif, but much more weakly, and only at 
much higher than physiological pH.45 Although Zn2+ was found 
bound to His3 (site IV), the respective site also involved Glu6 rather 
than the N-terminus or backbone amides, further emphasizing that 
caution must be applied when interpreting metal-binding data from 
short peptides.46 
Another site that might have been expected to be 
observed associated with Zn2+ is the free thiol at Cys34, as cysteine 
is a common Zn2+-binding ligand in protein structures. However, in 
none of our structures did we observe zinc-related electron density 
near Cys34. The Ellman’s reagent assay showed 0.27 molar 
equivalents of free cysteine (which refers to Cys34 since it is the 
only cysteine not involved in disulphide bonds). Therefore, it is 
possible that binding was prevented by cysteine oxidation, although 
in none of the structures any electron density for the respective 
oxygen atoms was observed. We note that it has been known for 
some time that Cys34 is not a major (primary or secondary) binding 
site for Zn2+ on HSA.17 More recent work on the HSA C34A mutant 
also demonstrated clearly that Cys34 is not required for either site 
A or B.9 The apparent inability of Cys34 to form a significant Zn2+-
binding site is most likely due to a lack of other potential metal-
coordinating residues located nearby. In accordance with this, 
Cys34 tends to be associated more with binding of complexes of 
very soft metal ions rather than 3d row metal ions; these include 
complexes containing Au+ and Pt2+.47,48 Even so, Cys34 was also not 
observed as a Pt2+ binding site in a recent crystallographic study.42 
Given our observations, it is conceivable that the Zn2+-single 
thiolate interaction may be too weak to be observed.  
 
Potential influence of soaking on zinc binding 
Additional crystal soaking after initial co-crystallization (5IIU, 5IIX 
and 5IJE) allowed for higher Zn2+ concentration in the drop while 
maintaining neutral pH, which, in turn, revealed several additional 
Zn2+-binding sites that could not be detected at lower Zn2+ 
concentrations. Soaking is a very popular technique used to 
introduce ligands into proteins, and it is assumed to produce 
essentially the same results as compared to co-crystallization when 
the final concentration of the ligand is the same. Nevertheless, one 
should keep in mind that it may possibly result in a different mode 
of ligand binding (as compared to co-crystallization) for various 
reasons. 1) The ligand may not have access to the binding site in the 
crystalline form. However, this issue is highly unlikely with small 
ligands like Zn2+ that can easily penetrate the crystal. 2) Some Zn2+-
binding sites located on the surface of the protein may be blocked 
during soaking due to crystal contact formation. In albumin, 
however, only 10% of the protein surface area is involved in crystal 
contacts as calculated using the PISA server.49 This is much lower 
than the average surface area buried by crystal contacts in protein 
crystal structures, which ranges from 15-49%.50 Taken together, this 
suggests that the majority of the surface in albumin crystals is not 
involved in crystal contacts, and so the accessibility of most Zn2+-
binding sites should not be affected by the crystal lattice formation. 
3) The formation of the lattice could prevent necessary 
conformational changes and hinder Zn2+ binding in some sites. This 
may apply to sites located near the crystal contacts (which is a rare 
case for albumin as mentioned in point 2) or to sites which require 
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massive conformational changes in order for Zn2+ to bind. All the 
other sites should possess the same conformational freedom (at 
least for amino-acid sidechains) in the crystal and in the solution, as 
was manifested by the conformational dynamics of His247 (vide 
supra). Taking all these considerations into account, we assume 
that observations made for soaked crystals – such as flipping of 
His247 and presence of additional Zn2+-binding sites – were a result 
of increased Zn2+ concentration, not the experimental procedure 
used to achieve the final Zn2+ concentration. 
 
 Zinc homeostasis in blood plasma 
The dissociation constants determined by ITC under near-
physiological conditions for the major zinc binding site in the low 
micromolar range, together with average concentrations for 
albumin and exchangeable zinc in plasma, allow estimating the free 
Zn2+ concentration as lying in the tens of nanomolar, if no other 
binding partners are considered. Although much higher than 
intracellular free Zn2+ concentrations, this extracellular 
concentration is low enough to avoid cell toxicity. At the same time, 
the binding of Zn2+ to albumin is both thermodynamically relatively 
weak and kinetically labile, and this facilitates dissociative Zn2+ 
transfer to other binding partners including cellular zinc uptake 
transporters and other plasma proteins.6 Thus, the extracellular 
Zn2+ buffer albumin regulates the availability of plasma Zn2+ for 
other processes. Crucially, previous work has shown that the Zn2+-
binding capacity of albumin is dependent on the presence of other 
metabolites, most importantly free fatty acids.13,14 Binding of these 
in fatty-acid binding site FA251 disrupts zinc site A (Fig. S4). Under 
these conditions, the secondary site(s) become significant; 
speciation modeling for human plasma has shown that due to the 
high concentration of albumin, its secondary sites still provide a 
relevant Zn2+ buffer. Even so, the free Zn2+ concentration was 
estimated to increase into the low micromolar range (≤ 1 µM) at the 
highest levels of fatty acid overload.14 Clearly, such an increase in 
non-albumin bound zinc is likely to increase Zn2+ association with 
other plasma proteins, and lead to increased cellular uptake, with 
multiple downstream effects.   
 
 Conclusions 
The adequate distribution of the essential nutrient Zn2+ throughout 
the body and its delivery to all cells is of fundamental importance. 
Here, for the first time we have illustrated details of Zn2+-albumin 
binding on the atomic level using X-ray crystallography. It is at these 
identified sites that the speciation and distribution of Zn2+ in the 
blood is controlled. In addition to metal ions, serum albumin also 
transports other physiologically important molecules such as fatty 
acids, hormones and drugs, with albumin emerging as a central hub 
in plasma that links the distribution of these major 
metabolites.6,14,52 At present there are over 120 albumin structures 
(predominantly of HSA) available in the RCSB Protein Databank. 
Collectively these structures contain information pertaining to 
conformational effects triggered by the binding of various small 
molecules to albumins. Establishing the precise location and 
properties of the main physiologically-relevant Zn2+ sites allows 
assessment of how binding of other molecules influences Zn2+ 
carriage by albumin. Such interplay is likely to regulate the activity 
of other Zn2+-binding plasma proteins, such as histidine-rich 
glycoprotein, influence cellular Zn2+ uptake, or in extreme cases 
could lead to cell damage due to Zn toxicity. Thus the presented 
data allow unprecedented insight into Zn2+ binding at several sites 
on the albumin molecule, providing a platform for exploring the 
dynamic interplay between Zn2+ and other physiologically important 
molecules transported by serum albumin. 
 
Experimental 
Mutation, Expression, Purification and Crystallization 
The coding sequence of human serum albumin (corresponding to 
residues 19-609 of the prepro-albumin sequence; NP_000468) was 
amplified and cloned into pKLAC2 plasmid using Xho/NotI 
restriction sites downstream and in frame with the α-mating factor 
secretion signal sequence. Oligonucleotide directed mutagenesis 
was used to prepare a construct encoding the mutated albumin 
(H67A) using the QuikChange Site-Directed Mutagenesis Kit 
(Agilent, Cheshire, UK). The resultant plasmids were linearized using 
BstXI enzyme and transformed into Kluyveromyces lactis GG799 
competent cells (New England Biolabs, Hitchin, UK) in accordance 
with the manufacturer’s instructions and grown under acetamide 
selection. Genomic DNA was extracted from resultant clones using 
the Wizard Yeast Genomic DNA Purification Kit (Promega, 
Southampton, UK) and correct insertion of the expression cassette 
into the K. lactis genome was verified by PCR, using primers flanking 
the insertion site. A colony expressing the required protein of 
Page 9 of 21 Chemical Science
C
he
m
ic
al
S
ci
en
ce
A
cc
ep
te
d
M
an
us
cr
ip
t
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
5 
A
ug
us
t 2
01
6.
 D
ow
nl
oa
de
d 
on
 2
5/
08
/2
01
6 
10
:4
8:
16
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
DOI: 10.1039/C6SC02267G
ARTICLE Chemical Science 
10 | Chemical Science, 2016, 00, 1-3 This journal is © The Royal Society of Chemistry 2016 
Please do not adjust margins 
Please do not adjust margins 
interest was grown overnight in 50 ml of sterile YPGlu medium (1% 
yeast extract, 2% Bacto-Peptone, 2% glucose) at 30°C with shaking 
at 200 rpm. This starter culture was used at ratio of 1/100 to 
inoculate 4 L of sterile YPGal (1% yeast extract, 2% Bacto-Peptone, 
2% galactose). The culture was grown for 3 days at 30°C with 
shaking at 200 rpm at pH 4.5-5.5. Finally, the supernatant was 
removed following centrifugation and purification proceeded by 
applying a concentrated sample of supernatant on HiTrap Blue HP 
(GE Healthcare, Little Chalfont, UK). This procedure was followed by 
anion exchange (HiTrap DEAE FF; GE Healthcare) and size exclusion 
(HiLoad Superdex-75 column; GE Healthcare) techniques. All 
preparations were performed on an ÄKTA Purifier (GE Healthcare). 
Final purity of protein by SDS-PAGE was >95%. Protein was dialyzed 
in 50 mM Tris, 140 mM NaCl, pH 7.4 prior to ITC Zn2+-binding 
experiments.  
For crystallization, ESA was purchased from Equitech-Bio 
(Kerrville, TX, LOT# ESA62-985, Catalog# ESA62) and HSA from 
Sigma-Aldrich (St. Louis, MO, LOT# SLBD7204, Catalog# A3782), 
both as defatted lyophilized powder. ESA was dissolved in 10 mM 
Tris pH 7.5 and 150 mM NaCl buffer and HSA was dissolved in 20 
mM K2HPO4 pH 7.5 buffer. Proteins were purified using a Superdex 
200 gel filtration column attached to an ÄKTA FPLC system (GE 
Healthcare) at 4°C. Following gel filtration, fractions containing 
monomeric proteins with the molecular weight of 55-60 kDa were 
selected and concentrated to 30 mg/ml for ESA and 90 mg/ml for 
HSA. 
 ZnCl2 (Sigma Aldrich, chemical grade ≥98%) was used to 
prepare crystallization conditions and stock solutions for crystals 
soaking. Since ZnCl2 is known to decrease pH of water solutions due 
to formation of Zn(OH)2, a special care was taken in order to control 
the pH of the final solutions. To assure the final pH in crystallization 
drop to be as intended (e.g. 4.5, 6.5, 6.9, 7.0, 7.4, 9.0), the pH in 
every zinc-containing crystallization condition was adjusted with 
NaOH prior to crystallization experiment. The solution of ZnCl2 used 
for crystals soaking was prepared by dissolving ZnCl2 in 100 mM Tris 
buffer to final concentration of 100 mM. The pH was adjusted to a 
chosen value.  
In order to obtain diffracting crystals of HSA-Zn2+ 
complexes, the sitting-drop vapour diffusion method was used on 
triple drop, 96-well crystallization plates from Hampton Research 
(Aliso Viejo, CA). Plates were set up using a Mosquito crystallization 
robot (TTP Labtech, Cambridge, MA). Both the standard setup and 
alternative reservoir methods53 were used with more than 10 
commercially available screens. All of the crystallization trials were 
attempted with varied Zn2+ (1- 20 mM) and protein concentrations 
(70 – 240 mg/ml), as well as with protein:reservoir ratios of 1:1, 1:2 
and 2:1. Crystals suitable for X-ray experiments grew only in 
condition no. 20 from the Wizard IV screen (25% (w/v) PEG 1500, 
100 mM MMT buffer pH 9.0) in the presence of 0.5 mM ZnCl2 (Table 
1). In addition, crystallization conditions of HSA structures 
deposited in the PDB were also tried with grid-screening 
optimizations by hanging-drop vapour diffusion method on 15-well 
plates (Qiagen, Valencia, CA). Crystals of HSA-Zn2+ complexes and 
native HSA (for soaking experiment) were grown using PDB 
conditions, but they did not diffract better than 4 Å. 
For ESA-Zn2+ complexes, more than 10 commercial 
screens were tested using the sitting-drop vapour diffusion method 
with the standard setup on 96-well plates. Screening gave several 
conditions with diffracting crystals. We selected two of them, one 
at acidic pH (2.0 M ammonium sufate, 100 mM sodium acetate pH 
4.5) and one at close to neutral pH (200 mM lithium sulfate, 100 
mM Tris:HCl, pH 7.0, 2.0 M ammonium sulfate) that were used for 
further optimization of ESA-Zn2+ complexes. Crystals were obtained 
by the hanging-drop vapour diffusion method on 15-well plates 
(Qiagen, Valencia, CA). Plates were set up manually with a 1:1 
protein:reservoir ratio. All ESA-Zn2+ complexes were crystallized in 
the presence of 2.5 or 50 mM ZnCl2. Additionally, selected crystals 
of ESA-Zn2+ complexes were soaked at higher ZnCl2 concentrations 
by adding 0.5-2.5 µl of 100 mM ZnCl2 in 100 mM Tris (Table 1). 
Crystallization and cryo-protectant conditions are summarized in 
Table 1.  
 
Data Collection and Anomalous Scattering 
Data were collected from single crystals at 100 K at the LS-CAT 21-
ID-F for HSA-Zn2+ and for ESA-Zn2+ at LS-CAT 21-ID-G and SBC-CAT 
19-BM beamlines at the Advanced Photon Source, Argonne 
National Laboratory (Argonne, IL). Diffraction images for HSA-Zn2+ 
and ESA-Zn2+ were collected at the selenium absorption K-edge 
(12664 eV), where anomalous scattering on Zn2+ is strong. The 
selected crystal of ESA in 30 mM ZnCl2 (5IJE) was scanned for X-ray 
fluorescence emission in order to confirm identity of the metal. 
Additionally, the identity of the bound metal for this crystal was 
confirmed by comparing diffraction data collected on wavelengths 
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corresponding to energies below (9618 eV) and above (9668 eV) the 
zinc absorption K-edge (9659 eV, Fig. S1).  
 
Structure Determination and Refinement 
Structures of HSA and ESA were solved by molecular replacement 
using native structures of both proteins (1AO6 for HSA and 3V08 for 
5IIH and afterwards 5IIH for the other four ESA structures) 
previously deposited in the PDB as template models. The data were 
integrated and scaled by HKL-300054 using scale anomalous mode, 
enabling calculation of an anomalous map during subsequent 
structure refinement. Molecular replacement was performed using 
MOLREP55 and other programs from the CCP4 package56 
incorporated into HKL-3000. The refinement was performed with 
REFMAC57 in HKL-3000. COOT58 was used for manual model 
inspection and real-space refinement. TLS was used in the final 
stages of the refinement, and TLS groups were introduced using the 
TLSMD server.59 A stand-alone version of MOLPROBITY60 
incorporated into HKL-3000 and the Worldwide PDB (wwPDB) 
validation server61 were used for structure quality assessment. Zn2+-
binding sites were additionally validated using the CheckMyMetal 
server.62 Data collection and refinement statistics are summarized 
in Table 2. The atomic coordinates and structure factors have been 
deposited in the PDB with identifiers: 5IJF, 5IIH, 5IIU, 5IIX, 5IJE and 
5IJ5. The diffraction images are available on Integrated Resource for 
Reproducibility in Macromolecular Crystallography website 
(http://proteindiffraction.org/) with doi:10.18430/M35IIH, 
doi:10.18430/M35IIU, doi:10.18430/M35IIX, doi:10.18430/M35IJ5, 
doi:10.18430/M35IJE, doi:10.18430/M35IJF. 
 
Isothermal Titration Calorimetry (ITC) 
Binding of Zn2+ to HSA, H67A mutant HSA, and ESA was assessed by 
ITC. In each case experiments were performed using a MicroCal VP-
ITC instrument (GE Healthcare). Proteins were dialyzed in 50 mM 
Tris, 140 mM NaCl, pH 7.4 prior to analysis. Prior to titration ZnCl2 
was added to the reaction buffer and the pH re-adjusted to 7.4. 
Samples were degassed for 15 minutes. All experiments were 
performed at 25 °C with 50 µM albumin samples and 1.5 mM ZnCl2. 
The parameters for each ITC experiment were set to one injection 
of 2 μl over 4 s followed by up to 55 injections of 5 μl over 10 s with 
an interval of 240 s between injections to allow complete 
equilibration. The stirring speed was set to 307 rpm. Heats of 
dilution were accounted for with blank titrations performed by 
titrating the ZnCl2 solution into reaction buffer and subtracting the 
averaged heat of dilution from the main experiments. Raw data 
were processed using MicroCal Origin software and data were fitted 
using the same software.  
 
Sequence and Structure Analysis 
Homology sequence search was performed using BLAST63 against 
UniProtKB database with default options. Sequences were aligned 
using the MAFFT server64 with default parameters. The SSM 
algorithm65 implemented in COOT was used to superpose 
structures and calculate RMSD values.  
 
Acknowledgments 
We would like to thank Jonathan Handing for critical reading and 
discussion. We would like to thank Karolina Majorek for 
crystallization and data collection of 5IJ5. We thank also beamline 
scientists, especially Randy Alkire and Norma Duke from SBC-CAT 
19-ID and 19-BM, for assistance in data collection. The structural 
data shown in this report used resources of the Advanced Photon 
Source, a U.S. Department of Energy (DOE) Office of Science User 
Facility operated for the DOE Office of Science by Argonne National 
Laboratory under Contract No. DE-AC02-06CH11357. Use of the LS-
CAT Sector 21 was supported by the Michigan Economic 
Development Corporation and the Michigan Technology Tri-
Corridor (Grant 085P1000817). The work described here was 
supported by NIH grants 5U54GM094662-05 and R01GM053163, 
BBSRC grant BB/J006467/1 and British Heart Foundation grant 
PG/15/9/31270.  
 
References 
 
1 T. J. Peters, Clin. Chem., 1977, 23, 5–12. 
2 G. Fanali, A. di Masi, V. Trezza, M. Marino, M. Fasano and 
P. Ascenzi, Mol. Aspects Med., 2012, 33, 209–290. 
3 X. M. He and D. C. Carter, Nature, 1992, 158, 209–215. 
4 W. Bal, M. Sokołowska, E. Kurowska and P. Faller, Biochim. 
Biophys. Acta - Gen. Subj., 2013, 1830, 5444–5455. 
5 E. L. Giroux and R. I. Henkin, Biochim. Biophys. Acta, 1972, 
273, 64–72. 
6 J. P. Barnett, C. a Blindauer, O. Kassaar, S. Khazaipoul, E. M. 
Martin, P. J. Sadler and A. J. Stewart, Biochim. Biophys. 
Acta, 2013, 1830, 5456–64. 
Page 11 of 21 Chemical Science
C
he
m
ic
al
S
ci
en
ce
A
cc
ep
te
d
M
an
us
cr
ip
t
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
5 
A
ug
us
t 2
01
6.
 D
ow
nl
oa
de
d 
on
 2
5/
08
/2
01
6 
10
:4
8:
16
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
DOI: 10.1039/C6SC02267G
ARTICLE Chemical Science 
12 | Chemical Science, 2016, 00, 1-3 This journal is © The Royal Society of Chemistry 2016 
Please do not adjust margins 
Please do not adjust margins 
7 D. J. Rowe and D. J. Bobilya, Proc Soc Exp Biol Med., 2000, 
224, 178–186. 
8 M. Gálvez, J. A. Moreno, L. M. Elósegui and J. F. Escanero, 
Biol. Trace Elem. Res., 2001, 84, 45–56. 
9 C. A. Blindauer, I. Harvey, K. E. Bunyan, A. J. Stewart, D. 
Sleep, D. J. Harrison, S. Berezenko and P. J. Sadler, J. Biol. 
Chem., 2009, 284, 23116–23124. 
10 H. Haase, S. Hebel, G. Engelhardt and L. Rink, Metallomics, 
2015, 7, 102–111. 
11 E. C. Tibaduiza and D. J. Bobilya, J. Cell. Physiol., 1996, 167, 
539–547. 
12 T. J. Peters, All About Albumin: Biochemistry, Genetics, and 
Medical Applications., Academic Press, San Diego, CA., 
1995. 
13 J. Lu, A. J. Stewart, D. Sleep, P. J. Sadler, T. J. T. Pinheiro 
and C. A. Blindauer, J. Am. Chem. Soc., 2012, 134, 1454–
1457. 
14 O. Kassaar, U. Schwarz-Linek, C. A. Blindauer and A. J. 
Stewart, J. Thromb. Haemost., 2015, 13, 101–110. 
15 E. Martins and T. Drakenberg, Inor. Chim. Acta, 1982, 67, 
71–74. 
16 J. Masuoka and P. Saltman, J. Biol. Chem., 1994, 269, 
25557–25561. 
17 P. J. Sadler and J. H. Viles, Inorg Chem., 1996, 35, 4490–
4496. 
18 J. Lu, A. J. Stewart, P. J. Sadler, T. J. T. Pinheiro and C. A. 
Blindauer, Biochem. Soc. Trans., 2008, 36, 1317–1321. 
19 W. Bal, J. Christodoulou, P. J. Sadler and A. Tucker, J. Inorg. 
Biochem., 1998, 70, 33–39. 
20 A. J. Stewart, C. A. Blindauer, S. Berezenko, D. Sleep and P. 
J. Sadler, Proc. Natl. Acad. Sci. U. S. A., 2003, 100, 3701–
3706. 
21 M. Sokolowska, M. Wszelaka-Rylik, J. Poznanski and W. Bal, 
J. Inorg. Biochem., 2009, 103, 1005–1013. 
22 W. Goumakos, J. P. Laussac and B. Sarkar, Biochem Cell 
Biol, 1991, 69, 809–820. 
23 F. Y. Wu and C. W. Wu, Annu. Rev. Nutr., 1987, 7, 251–272. 
24 A. Bujacz, Acta Crystallogr. D. Biol. Crystallogr., 2012, 68, 
1278–1289. 
25 K. A. Majorek, P. J. Porebski, A. Dayal, M. D. Zimmerman, K. 
Jablonska, A. J. Stewart, M. Chruszcz and W. Minor, Mol. 
Immunol., 2012, 52, 174–182. 
26 S. Lejon, I.-M. Frick, L. Björck, M. Wikström and S. 
Svensson, J. Biol. Chem., 2004, 279, 42924–42928. 
27 S. Sugio, A. Kashima, S. Mochizuki, M. Noda and K. 
Kobayashi, Protein Eng., 1999, 12, 439–446. 
28 B. Decock-Le Reverend, B. Perly and B. Sarkar, Biochim. 
Biophys. Acta, 1987, 18, 12–27. 
29 A. Bijelic, S. Theiner, B. K. Keppler and A. Rompel, J. Med. 
Chem., 2016, acs.jmedchem.6b00600. 
30 B. E. Fischer, U. K. Häring, R. Tribolet and H. Sigel, Eur. J. 
Biochem., 1979, 94, 523–530. 
31 L. Bologni, A. Sabatini and A. Vacca, Inorg. Chim. Acta, 
1983, 69, 71–75. 
32 M. M. Harding, Acta Crystallogr. Sect. D Biol. Crystallogr., 
2004, 60, 849–859. 
33 K. A. McCall, C. Huang and C. A. Fierke, J Nutr, 2000, 1455–
1458. 
34 J. M. Argüello, D. Raimunda and M. González-Guerrero, J. 
Biol. Chem., 2012, 287, 13510–13517. 
35 C. A. Blindauer, Chem. Commun., 2015, 51, 4544–4563. 
36 J. Newman, R. A. Sayle and V. J. Fazio, Acta Crystallogr. 
Sect. D Biol. Crystallogr., 2012, 68, 1003–1009. 
37 Z. Wang, J. X. Ho, J. R. Ruble, J. Rose, F. Rüker, M. 
Ellenburg, R. Murphy, J. Click, E. Soistman, L. Wilkerson and 
D. C. Carter, Biochim. Biophys. Acta, 2013, 1830, 5356–
5374. 
38 O. J. Bos, J. F. Labro, M. J. Fischer, J. Wilting and L. H. 
Janssen, J. Biol. Chem., 1989, 264, 953–959. 
39 M. Dockal, J. Biol. Chem., 2000, 275, 3042–3050. 
40 K. Kaneko, V. T. G. Chuang, A. Minomo, K. Yamasaki, N. V. 
Bhagavan, T. Maruyama and M. Otagiri, IUBMB Life, 2011, 
63, 277–285. 
41 J. H. Galla, B. F. Palmer and R. J. Alpern, J. Am. Soc 
.Nephrol., 2000, 11, 1462–1469. 
42 G. Ferraro, L. Massai, L. Messori and A. Merlino, Chem. 
Commun., 2015, 51, 9436–9439. 
43 C. Harford and B. Sarkar, Acc. Chem. Res., 1997, 30, 123–
130. 
44 P. F. Predki, C. Harford, P. Brar and B. Sarkar, Biochem. J., 
1992, 287, 211–215. 
45 H. Lakusta and B. Sarkar, J. Inorg. Biochem., 1979, 11, 303–
315. 
46 M. Sokolowska, A. Krezel, M. Dyba, Z. Szewczuk and W. Bal, 
Eur. J. Biochem., 2002, 269, 1323–1331. 
47 J. Christodoulou, P. J. Sadler and A. Tucker, Eur. J. 
Biochem., 1994, 225, 363–368. 
48 A. Sugii, K. Nishimura, K. Harada, M. Nakayama and S. 
Masuda, Chem. Pharm. Bull., 1991, 39, 408–410. 
49 E. Krissinel and K. Henrick, J. Mol. Biol., 2007, 372, 774–
797. 
50 O. Carugo and P. Argos, Protein Sci., 1997, 2261–2263. 
51 S. Curry, H. Mandelkow, P. Brick and N. Franks, Nat. Struct. 
Biol., 1998, 5, 827–835. 
52 J. Lu, A. J. Stewart, P. J. Sadler, T. J. T. Pinheiro and C. A. 
Page 12 of 21Chemical Science
C
he
m
ic
al
S
ci
en
ce
A
cc
ep
te
d
M
an
us
cr
ip
t
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
5 
A
ug
us
t 2
01
6.
 D
ow
nl
oa
de
d 
on
 2
5/
08
/2
01
6 
10
:4
8:
16
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
DOI: 10.1039/C6SC02267G
Chemical Science  ARTICLE 
This journal is © The Royal Society of Chemistry 2016 Chemical Science, 2013, 00, 1-3 | 13 
Please do not adjust margins 
Please do not adjust margins 
Blindauer, J. Med. Chem., 2012, 55, 4425–4430. 
53 J. Newman, Acta Crystallogr. Sect. D Biol. Crystallogr., 
2005, 61, 490–493. 
54 W. Minor, M. Cymborowski, Z. Otwinowski and M. 
Chruszcz, Acta Crystallogr. D. Biol. Crystallogr., 2006, 62, 
859–866. 
55 A. Vagin and A. Teplyakov, J. Appl. Crystallogr., 1997, 30, 
1022–1025. 
56 M. D. Winn, C. C. Ballard, K. D. Cowtan, E. J. Dodson, P. 
Emsley, P. R. Evans, R. M. Keegan, E. B. Krissinel, A. G. W. 
Leslie, A. McCoy, S. J. McNicholas, G. N. Murshudov, N. S. 
Pannu, E. A. Potterton, H. R. Powell, R. J. Read, A. Vagin 
and K. S. Wilson, Acta Crystallogr. D. Biol. Crystallogr., 
2011, 67, 235–242. 
57 G. N. Murshudov, P. Skubák, A. A. Lebedev, N. S. Pannu, R. 
A. Steiner, R. A. Nicholls, M. D. Winn, F. Long and A. A. 
Vagin, Acta Crystallogr. D. Biol. Crystallogr., 2011, 67, 355–
367. 
58 P. Emsley and K. Cowtan, Acta Crystallogr. D. Biol. 
Crystallogr., 2004, 60, 2126–2132. 
59 J. Painter and E. A. Merritt, J. Appl. Crystallogr., 2006, 39, 
109–111. 
60 V. B. Chen, W. B. Arendall, J. J. Headd, D. A. Keedy, R. M. 
Immormino, G. J. Kapral, L. W. Murray, J. S. Richardson and 
D. C. Richardson, Acta Crystallogr. D. Biol. Crystallogr., 
2010, 66, 12–21. 
61 R. J. Read, P. D. Adams, W. B. Arendall, A. T. Brunger, P. 
Emsley, R. P. Joosten, G. J. Kleywegt, E. B. Krissinel, T. 
Lütteke, Z. Otwinowski, A. Perrakis, J. S. Richardson, W. H. 
Sheffler, J. L. Smith, I. J. Tickle, G. Vriend and P. H. Zwart, 
Structure, 2011, 19, 1395–1412. 
62 H. Zheng, M. D. Chordia, D. R. Cooper, M. Chruszcz, P. 
Müller, G. M. Sheldrick and W. Minor, Nat. Protoc., 2014, 
9, 156–170. 
63 S. F. Altschul, T. L. Madden, A. A. Schäffer, J. Zhang, Z. 
Zhang, W. Miller and D. J. Lipman, Nucleic Acids Res., 1997, 
25, 3389–3402. 
64 K. Katoh and D. M. Standley, Mol. Biol. Evol., 2013, 30, 
772–780. 
65 E. Krissinel and K. Henrick, Acta Crystallogr. D. Biol. 
Crystallogr., 2004, 60, 2256–2268.  
Page 13 of 21 Chemical Science
C
he
m
ic
al
S
ci
en
ce
A
cc
ep
te
d
M
an
us
cr
ip
t
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
5 
A
ug
us
t 2
01
6.
 D
ow
nl
oa
de
d 
on
 2
5/
08
/2
01
6 
10
:4
8:
16
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
DOI: 10.1039/C6SC02267G
  
 
 
Crystal structure of ESA in complex with Zn2+. All structures of ESA-Zn2+ presented herein are superposed 
and a single Zn2+ for each site is shown as a representative. The overall fold in the 5IIH structure is shown 
as representative. Helices are represented by ribbons and Zn2+ by red spheres. Zn2+ binding sites are 
marked with numbers I-XV as in Table 3.  
Fig. 1  
83x40mm (300 x 300 DPI)  
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The all-atoms superposition of residues within 8 Å from Zn2+ in site A of HSA-Zn2+ complex (5IJF, blue), and 
corresponding residues in (A) native HSA structure (1AO6, white) and (B) ESA-Zn2+ structure (2.5 mM 
Zn2+, pH 7.4 – 5IIH, green). Zinc ions are shown in grey, oxygen in red, sulfur in yellow, nitrogen in dark 
blue, coordination bonds with Zn2+ ion are marked with black dashed lines. Residue numbers refer to HSA.  
Fig. 2  
85x42mm (300 x 300 DPI)  
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Representative structures showing dynamic behavior of His247 in ESA-Zn2+ complexes. (A) ESA-Zn2+, 2.5 
mM Zn2+, pH 7.4; 5IIH. (B) ESA-Zn2+, 30 mM Zn2+ , pH 7.4; 5IJE. (C) ESA-Zn2+, 15 mM Zn2+, pH 6.5; 5IIX. 
Residues are shown in sticks representation, zinc ion in grey, oxygen in red, nitrogen in dark blue, carbon in 
green. Coordination bonds are marked with black dashed lines. Grey grid represents 2mFo – DFc map (σ – 
1.0), orange – anomalous map (σ - 3.0).  
Fig. 3  
56x18mm (300 x 300 DPI)  
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Secondary Zn2+ binding sites in the structures of ESA. Sites are numbered as in Table 3; only those 
coordinated by at least two protein residues are shown. Residues are shown in sticks representation, zinc 
ion in grey, oxygen in red, nitrogen in dark blue, carbon in green. Coordination bonds are marked with black 
dashed lines. Grey grid represents 2mFo – DFc map (σ – 1.0), orange – anomalous map (σ - 3.0). Residue 
numbers refer to HSA; in case of non-conserved residues, the HSA amino acid is given in parentheses.  
Fig. 4  
161x152mm (300 x 300 DPI)  
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Measurement of Zn2+ binding affinity to HSA, H67A HSA mutant, and ESA by ITC. (A) ITC data for Zn2+ 
binding to HSA and the H67A mutant form. (B) ITC data for Zn2+ binding to ESA. In all cases the respective 
protein (50 µM) was titrated with 5 µl injections of a 1.5 mM ZnCl2 solution for 55 injections.  
Fig. 5  
106x66mm (300 x 300 DPI)  
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Tables 
Table 1. Crystallization and cryo-protection conditions for the crystal structures of HSA and 
ESA in complex with Zn2+. 
PDB ID 
Albumin 
Zn2+ conc. (mM) 
pH 
5IJF 
HSA 
0.5 
9.0 
5IIH 
ESA 
2.5 
7.4 
5IIU 
ESA 
10 
6.9 
5IIX 
ESA 
15 
6.5 
5IJE 
ESA 
30 
7.4 
5IJ5 
ESA 
50 
4.5 
Albumin 
Final conc. in the 
crystallization drop 
(mM) 
HSA 
0.7 
ESA 
0.2 
Crystallization 
conditions 
Used to mix in 1:1 
ratio with protein 
sample 
100 mM MMT (DL-
Malic acid, MES 
monohydrate, Tris) pH 
9.0, 
23% w/v PEG 1500, 
1 mM ZnCl2 
200 mM Li2SO4 
100 mM Tris:HCl pH 7.4 / 6.9 / 6.5 
/7.4 
2.0 M (NH4)2SO4 
5 mM ZnCl2  
2.0 M (NH4)2SO4 
100 mM Na 
acetate, pH 4.5 
100 mM ZnCl2 
Soaking No No Yes Yes Yes No 
ZnCl2  
Final conc. in the 
crystallization drop 
(mM) 
0.5 2.5 10 15 30 50 
Crystallization 
temperature 
21 °C 21 °C 
 
 
 
21 °C 
Additional cryo-
protectant 
None Paratone-N 50% Paratone-N, 
50% Mineral Oil 
 
Table 2. Data collection and refinement statistic for HSA-Zn2+ and ESA-Zn2+ structures. Values 
in parentheses are for the highest resolution shell. 
PDB ID 
Albumin 
Zn2+ conc. (mM) 
pH 
5IJF 
HSA 
0.5 
9.0 
5IIH 
ESA 
2.5 
7.4 
5IIU 
ESA 
10 
6.9 
5IIX 
ESA 
15 
6.5 
5IJE 
ESA 
30 
7.4 
5IJ5 
ESA 
50 
4.5 
Data collection 
Wavelength (Å, keV) 
0.979, 
12664 
0.979, 
12664 
0.979, 
12664 
0.979, 
12664 
1.282, 9668 
1.289, 9618 
0.979, 
12664 
Space group C2221 P61 P61 P61 P61 P61 
Unit-cell parameters  
a, b, c (Å) 
α, β, γ (°) 
78.6,  
121.6,  
140.0 
90.0, 90.0, 
90.0 
93.10, 
93.10, 
141.44 
90.0, 90.0, 
120.0 
93.75, 
93.75, 
141.79 
90.0, 90.0, 
120.0 
94.31, 
94.31, 
141.49 
90.0, 90.0, 
120.0 
94.38, 
94.38, 
141.91 
90.0, 90.0, 
120.0 
96.13, 
96.13, 
144.15 
90.0, 90.0, 
120.0 
Resolution range (Å) 50.0 – 2.65 50.0 – 2.40 80.0 – 2.30 80.0 – 2.20 50.00 - 2.40 50.00 - 2.55 
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(2.70 – 2.65) (2.44 – 2.40) (2.34 – 2.30) (2.24 – 2.20) (2.40 - 2.44) (2.55 - 2.59) 
Completeness (%) 98.9 (88.4) 99.6 (99.3) 99.3 (99.0) 100 (100) 99.5 (99.9) 99.9 (100.0) 
Total number of 
reflections 
143674 208207 300971 277833 120428 151772 
No. of unique 
reflections  
19741 25677 31099 36226 27885 23268 
Mean I/σ(I) 28.7 (2.1) 32.2 (2.1) 29.1 (1.9) 31.1 (2.2) 23.0 (2.1) 23.8 (2.0) 
CC ½ - highest 
resolution shell 
0.84 0.85 0.89 0.89 0.79 0.70 
Redundancy 7.3 (6.6) 7.7 (7.7) 9.7 (9.4) 7.7 (7.5) 4.3 (4.1) 6.2 (5.7) 
Rmerge* (%) 7.1 (82.0) 7.1 (96.5) 7.8 8.9 (79.5) 7.9 (70.7) 0.107  
Structure refinement 
Rwork  (%) 21.3 17.5 17.9 17.8 19.5 18.9 
Rfree  (%) 29.2 23.5 23.9 22.8 25.5 25.3 
Bond lengths rmsd (Å) 0.008 0.009 0.008 0.008 0.008 0.044 
Bond angles rmsd (°) 1.2 1.2 1.2 1.2 1.2 1.2 
Mean B value (Å²) 105 72 62 58 55 76 
Number of protein 
atoms 
4279 4501 4514 4484 4463 4411 
Mean B value for 
protein atoms (Å²) 
105 72 62 58 56 76 
Number of water 
molecules 
40 133 193 364 296 159 
Mean B value for water 
molecules (Å²) 
85 61 56 57 50 66 
Number of ligands/ions 
atoms 
9 6 15 50 18 21 
Mean B value for 
ligands/ions atoms (Å²) 
92 110 86 74 73 94 
Clashscore 0.97 0.79 0.79 0.45 0.92 0.58 
Clashscore percentile  100 100 100 100 100 100 
Rotamer outliers (%) 0.24 0.83 0.83 0.21 0.64 0.66 
Ramachandran outliers 
(%) 
0.00 0.00 0.00 0.00 0.00 0.00 
Ramachandran favored 
(%) 
97.71 98.27 97.93 98.25 98.62 98.10 
Residues with bad 
bonds (%) 
0.00 0.00 0.00 0.00 0.00 0.00 
Residues with bad 
angles (%) 
0.00 0.00 0.00 0.00 0.00 0.00 
MolProbity score 0.85 0.75 0.77 0.66 0.78 0.69 
	
∗
  ∑ ∑ |  〈〉| ∑ ∑ ,⁄  where ‹I(hkl)› is the mean of I 
observations Ii(hkl) of reflection hkl. 
	and	  ∑ || |  | !|| ∑| |⁄	 ,where Fo and Fc are the observed and calculated 
structure factors, respectively, calculated for working set (Rwork) and for 5% of the data omitted 
from refinement (Rfree). 
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Table 3. Summary of metal binding sites that have at least one protein ligand in different 
structures of HSA and ESA in complex with Zn2+. ‘x’ indicates that site is present in the 
structure.  ‘*’ indicates that anomalous signal is present in the site, but at least one of the 
coordinating residues observed in other structures is not present in Zn2+ vicinity due to disorder 
or different conformation of the sidechain. ‘#’ indicates that Zn2+ could not be modeled in the 
location, see text for details. Residue numbers refer to HSA; in case of non-conserved residues, 
the HSA amino acid is given in parentheses. 
PDB ID 
Albumin 
Zn2+ conc. (mM) 
pH 
5IJF 
HSA 
0.5 
9.0 
5IIH 
ESA 
2.5 
7.4 
5IIU 
ESA 
10 
6.9 
5IIX 
ESA 
15 
6.5 
5IJE 
ESA 
30 
7.4 
5IJ5 
ESA 
50 
4.5 
Site N
o
 Classification Coordinating residues       
I Primary His67, His247, Asp249 x x x    
I’ (Site A) His67, Asp249    x x x 
II Secondary His9, Asp13, Asp255 #  x    
III Secondary 
His157 (Phe), His288, 
Glu153 
  x x x x 
IV Tertiary His3, Glu6   x x x x 
V Tertiary 
Asp38, Ala78 (main chain 
oxygen) 
   x *  
VI Tertiary 
Glu97, Glu100 (crystal 
contact) 
     x 
VII Tertiary His318 (Ser), Asp312 (Asn)   x x x x 
VIII Tertiary His510, Asp512   x * x x 
IX Tertiary His338, Asp340   x    
X Tertiary His18 (Asn)   x x x x 
XI Tertiary Glu57   x   x 
XII Tertiary His146   x x x x 
XIII Tertiary His242    x x x 
XIV Tertiary His247     x x 
XV Tertiary His452 (Tyr)    x x x 
XVI Tertiary Asp479 (Glu)      x 
XVII Tertiary Glu518    x x x 
XVIII Tertiary His534      x 
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